April 16, 2020

Snehal Patel
Chief Executive Officer
Greenwich LifeSciences, Inc.
2311 Spartan Trail
Sugar Land, TX 77479

       Re: Greenwich LifeSciences, Inc.
           Amendment No. 1 to
           Draft Registration Statement on Form S-1
           Submitted April 7, 2020
           CIK No. 0001799788

Dear Mr. Patel:

      We have reviewed your amended draft registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

        Please respond to this letter by providing any requested information
and by publicly
filing your registration statement and non-public draft submission on EDGAR. If
you do not
believe our comments apply to your facts and circumstances or do not believe an
amendment is
appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Amendment No. 1 to Draft Registration Statement filed April 7, 2020

Business
Large Initial & Expandable Breast Cancer Market, page 59

1.    We note your response to comment 10. However, with the information
provided, we are
      unable to discern the basis for your claim of "Multi $ Billion Revenue
Potential." Please
      revise your disclosure to provide adequate support for this statement or
remove it.
Executive and Director Compensation, page 76

2.    We note your response to comment 14. Please revise footnote 2 to the
Summary
      Compensation Table and footnote 4 to the Non-Employee Director
Compensation table to
 Snehal Patel
Greenwich LifeSciences, Inc.
April 16, 2020
Page 2
       disclose the number of shares of common stock the Company paid the
respective
       individuals in exchange for related party payables and/or for warrants
to purchase shares
       of the Company's common stock.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

        We also remind you that your registration statement must be on file no
later than 48 hours
prior to the requested effective date and time. Refer to Rules 460 and 461
regarding requests for
acceleration. Please allow adequate time for us to review any amendment prior
to the requested
effective date of the registration statement.

       You may contact Jenn Do at 202-551-3743 or Terence O'Brien at
202-551-3355 if you
have questions regarding comments on the financial statements and related
matters. Please
contact David Gessert at 202-551-2326 or Michael Clampitt at 202-551-3434 with
any other
questions.



                                                            Sincerely,
FirstName LastNameSnehal Patel
                                                            Division of
Corporation Finance
Comapany NameGreenwich LifeSciences, Inc.
                                                            Office of Life
Sciences
April 16, 2020 Page 2
cc:       Jeffrey J. Fessler, Esq.
FirstName LastName